8:30 am Check-In & Coffee
9:20 am Chair’s Opening Remarks
Revolutionising ADC Design: Exploring Innovations & Strategies With Enhanced Therapeutic Efficacy
9:30 am Revisiting the Dogma of Antibody Drug Conjugates: A Data-Driven Perspective
Synopsis
- Understanding different types of linker instabilities and the potential implications of designing ADCs with overly stable linkers
- Questioning the ability of ADCs to deliver drugs exclusively to cancer cells while sparing normal cells
- Analyzing ADC clinical data to establish correlations between efficacy, toxicities, and drug-linker technologies
10:00 am Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology
Synopsis
- AJICAP®️ Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
- AJICAP®️ Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
- Showcasing Bispecific and Trispecific antibodies produced by fully-chemical conjugation technology
10:30 am Novel MMAU Auristatin Glycoside ADC Against Melanoma – Stabilised Hydrophilic Linker-Payload Provides A Wide Therapeutic Window & Improved Potency
Synopsis
- Review novel auristatin ADCs based on MMAU payload enable widening of therapeutic window compared to vedotin ADCs
- Discuss how high systemic and metabolic stability of cleavable glycopeptide linker improved both in vivo efficacy and tolerability
- Assess DAR4 and DAR8 MMAU ADCs against solid and heme malignancies
11:00 am Technology Slam & Morning Networking
Synopsis
As you enjoy your afternoon refreshments, you will also have the chance to be face-to-face with the field’s most innovative and exciting technology providers. Join our dedicated technology slam to identify your next technology provider and progress your antibody-drug conjugate pipeline smoothly and efficiently
Discovery Chemistry
Chair: Lolke de Haan, Chief Medical Officer, ADC Therapeutics
The Next Era of ADC Formats: Cashing In on ADC Precision & Turbocharging Therapeutic Efficacy
Download the Full Event Guide for full details
12:00 The Discovery of a New Degrader Antibody Conjugate (DAC)
Stephanie Monson, Principal Scientist, Genentech
12:30 Molecular Evolution of OncoFAP for the Tumor-Targeted Delivery of Biocidal Radionuclides & Cytotoxic Payloads
Andrea Galbiati, Senior Scientist, Philochem
1:00 pm Lunch & Learn With Merck
Discovery Chemistry
Next-Generation Approaches to Target Selection: Advancing ADC Precision for Improved Delivery & Reduced Toxicity
Download the Full Event Guide for full details
2:00 Oxford Biotherapeutics’ OGAP Target Discovery Platform: Use of Quantitative Membrane Tissue Proteomics to Identify new ADC Drug Target
Benjamin Thomas, Senior Director - USA & UK External Innovation Operations, Oxford Biotherapeutics
2:30 Drug Conjugates Targeting HER2 & HER3, Based On Engineered Affibody Molecules
Torbjorn Graslund, Associate Professor, KTH Royal Institute of Technology
3:00 End of Discovery Stream
3:30 pm Afternoon Break & Networking
Exploring The ADC Commercial Landscape: Insights & Perspectives for Market Success
4:00 pm Panel Discussion: Partnerships & Collaborations: Leveraging Alliances for ADC Market Success
Synopsis
- Exploring the value of forming partnerships to accelerate ADC development, leveraging expertise and resources
- Discussing how collaborations can facilitate market penetration, regional expansion, and increased patient access to ADC therapies
- Sharing risks and rewards – highlighting the benefits of sharing costs, risks, and intellectual property in ADC partnerships, leading to mutual success in a competitive landscape
5:00 pm Licensing Boom: The Dynamic Ecosystem of ADC Industry
Synopsis
- Unveiling key trends of collaboration in ADC industry
- What’s behind the landmark collaborations between DualityBio and various partners?
- Evaluate how the ecosystem and collaborations in ADC industry will evolve in the future